BerGenBio

BerGenBio ASA

The company develops AXL kinase inhibitors to treat aggressive diseases and cancers for healthcare providers and patients.

Myosin Therapeutics

This biopharmaceutical company develops small molecule therapies targeting molecular nanomotors to treat aggressive cancers and neurological disorders for patients with unmet medical needs.

APIM Therapeutics AS

This clinical-stage biotechnology company develops peptide drugs targeting cellular stress responses to treat patients with advanced solid tumours and multiple cancers.

Oncopeptides AB

This biotech company develops targeted therapies for patients with difficult-to-treat hematological diseases, specifically focusing on multiple myeloma treatments.

MyCural Therapeutics

This company develops small molecule drugs targeting the MYC oncoprotein to treat patients with aggressive, high-risk cancers.

Carrick Therapeutics

This biopharmaceutical company develops precision oncology therapies for patients with aggressive cancers, focusing on small molecules and inhibitors for solid tumours.

Nuvectis Pharma

This biopharmaceutical company develops precision medicines and targeted small molecule therapeutics for patients with advanced cancers and other serious conditions.

Adcendo

This clinical-stage biotechnology company develops antibody-drug conjugates to treat patients with various types of cancer and high unmet medical needs.